Bio-Analytical Co-op-Northeastern Students
Boost your chances before you apply.
Seaport Therapeutics
Boston, MA, US
Summary
The co-op will assist the Discovery team by executing in vitro experiments using LC-MS to screen lipid prodrugs and processing in vivo samples to generate DMPK data. They will also contribute to the optimization of LC-MS methods and document all experimental findings.
Job Description
Seaport Therapeutics is a clinical-stage therapeutics company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. The Company has a proven strategy of advancing clinically validated mechanisms previously held back by limitations that are overcome with its proprietary GlyphTM technology platform. All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce hepatotoxicity and other side effects. Seaport is led by an experienced team that invented and advanced important neuropsychiatric medicines and are guided by an extensive network of renowned scientists, clinicians and key opinion leaders. For more information, please visit www.seaporttx.com.
Job Description
Seaport Therapeutics is seeking a co-op student for a lab-based bioanalysis position to be part of our Discovery team. This co-op will have a focus on LC-MS to assist in the screening of novel drugs. We are looking for a highly motivated individual who is looking to be a part of a multidisciplinary team and to gain experience in a startup environment. This position will contribute to advancing the pipeline of impactful candidates generated from our novel Glyph™ prodrug platform.
Some of the responsibilities will include:
- Executing in vitro experiments, using LC-MS, for the screening of lipid prodrugs to support preclinical discovery
- Processing and analyzing in vivo samples (plasma, lymph fluid, etc.) to generate DMPK data for various prodrugs
- Contributing to the development and optimization of LC-MS methods for both quantitative and qualitative analysis
- Routine use and troubleshooting of LC-MS instrumentation
- Documenting all experiments using an electronic notebook and analyzing data for reports and regular internal presentations
Experience and Skills
- Enrolled in a Chemistry, Biochemistry, Pharmaceutical Sciences, Chemical Engineering, or related program at the Master’s Level
- Previous Co-op or lab experience is preferred
- Knowledge of or experience with: HPLC, reverse phase chromatography, mass spectrometry instrumentation, enzyme kinetics, protein precipitation, liquid-liquid extraction
- Strong organizational skills, attention to detail, and eagerness to learn.
Seaport Therapeutics (Nasdaq: SPTX) is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Through our differentiated approach, we identify clinically validated mechanisms with established efficacy and safety which had historically been limited by high first-pass metabolism, low bioavailability, and/or side effects. We apply our proprietary Glyph platform to overcome those limitations and invent innovative oral therapies. With an experienced team of industry leaders, Seaport has a proven track record in neuropsychiatry drug discovery and development and delivering successful business outcomes. Seaport aims to develop novel, leading treatment options that will make a significant impact for patients and their families.
For more information, please visit www.seaporttx.com or connect with us on X (formerly Twitter) @SeaportTx
Company size
51-200 employees
Industry
Biotechnology Research
Org type
Public Company
Headquarters
Boston, Massachusetts
Seaport Therapeutics (Nasdaq: SPTX) is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Through our differentiated approach, we identify clinically validated mechanisms with established efficacy and safety which had historically been limited by high first-pass metabolism, low bioavailability, and/or side effects. We apply our proprietary Glyph platform to overcome those limitations and invent innovative oral therapies. With an experienced team of industry leaders, Seaport has a proven track record in neuropsychiatry drug discovery and development and delivering successful business outcomes. Seaport aims to develop novel, leading treatment options that will make a significant impact for patients and their families.
For more information, please visit www.seaporttx.com or connect with us on X (formerly Twitter) @SeaportTx
Company size
51-200 employees
Industry
Biotechnology Research
Org type
Public Company
Headquarters
Boston, Massachusetts